SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
REDWOOD CITY, Calif., Oct. 24, 2016 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2016 after the close of trading on Thursday, November 3, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 96290958. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.
A replay of the call will be available beginning November 3, 2016 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on November 4, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 96290958. The webcast will also be available on Avinger's website for one year following the completion of the call.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with Peripheral Artery Disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular™ platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox OCT imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided Atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
“Avinger,” “Lumivascular,” “Lightbox,” “Ocelot,” “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
